Company intelligence / Profile preview
Rize Oncology Inc.
Kelowna, British Columbia, Canadarizeoncology.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Rize Oncology is developing STS-201, a small molecule drug candidate for the treatment of soft tissue sarcoma. The drug has shown significant utility in soft tissue sarcoma and other cancer types. STS-201's mechanism of action includes blocking cell division at the late G2/M boundary, slowing tumor proliferation, increasing oxygen in the tumor microenvironment, and forming more complete tumor vasculature to reduce metastasis.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Rize Oncology Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rize Oncology Inc..